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What are the new concepts about HDL?
HDL is the smallest and densest of the lipoproteins
because of its high protein content. Proteins make up about
50% of its mass and apolipoprotein A-I (apoA-I) accounts
for 70% of that protein component. There are several
mechanisms by which HDL protects against atherosclerosis,
including reverse cholesterol transport, anti oxidant effects,
anti-inflammatory effects, anti-thrombotic effects, and
modification of endothelial function. HDL has been proven
to be inversely related to stroke risk. HDL function rather
than its absolute level  may predict atherosclerotic disease
better in some subsets of patients where the HDL functions
as perhaps pro inflammatory. This explains those patients
who develop coronary artery disease and stroke despite very
high HDL levels. 
What do the Current Guidelines Recommend?
The Adult Treatment Panel (ATP) and American
Diabetes Association (ADA) guidelines recommend that
dyslipidemic therapy be geared at achieving target LDL-C
goals in personswith low HDL-C levels and that serum
HDL-C levels are a secondary target. The Expert Group on
HDL, a working group reporting on low HDL-C levels,
advised additional treatment with a fibrate or niacin in
persons with diabetes, the metabolic syndrome, or HDL
levels <40 mg/dL.
What are the available drugs?
Fibrates:
Raising HDL and lowering triglycerides with
gemfibrozil has been shown to reduce major cardiovascular
events, even in the absence of LDL-lowering. The reduction
in stroke risk with gemfibrozil treatment was evident after 6
months, and those with the lowest HDL-C at baseline seemed
most likely to benefit from treatment.
Niacin:
Niacin doses of 1 to 2 g per day can increase in HDL-
C of 20% to 30%. The extended-release (ER) niacin
preparationniaspan is better tolerated. Trials of niacin in
cardiovascular disease have not evaluated stroke as an
independent end point.
Statins:
Statins have been shown to reduce the risk of
ischaemic stroke by about 20% in multiple large studies.
Each 10% reduction in LDL-C is estimated to reduce the risk
of stroke by 15.6%.The effect of statins may vary among
patients, with those with low HDL-C and elevated
triglycerides more likely to benefit from statin therapy.
Combination Therapy:
Combination therapy may hold the key to the most
dramatic increase in HDL-C, and combinations of statin and
niacin have demonstrated 18% to 21% increase in HDL-C.
The HDL Atherosclerosis Treatment Study (HATS)
highlighted the benefits of combining statin therapy with
niacin where major clinical events were reduced and
atherosclerosis halted at angiographic level. ARBITER-2
study demonstrated that ER-niacin added to statin therapy
may halt the progression of atherosclerosis, as measured by
carotid intimamedia thickness among CHD patients with low
HDL-Clevels.
VA-HIT Trial:
This trial was done from September 1991 to August
1998 and it demonstrated that CHD events were significantly
reduced by treating patients with the fibric acid derivative
gemfibrozil1200 mg/d when the predominant lipid
abnormality was low HDL. CHD events were reduced by
11%with gemfibrozil for every 5-mg/dL (0.13-mmol/L)
increase in HDL-C. During gemfibrozil treatment, only the
increase in HDL C significantly predicteda lower risk of CHD
events; by multivariable analysis, neither triglyceride norLDL-
C levels at baseline or during the trial predicted CHD events.
What does this mean for clinicians practicing
in Pakistan?
All these studies reinforce the fact that dyslipidaemia
is a vascular risk factor and controlling our patients' bad
cholesterol and improving their good cholesterol is crucial for
prevention of further vascular events. Pakistani population's
food habits and the recent trends towards refined diet and fast
food are all leading to an increase in the number of population
at risk of vascular events. This calls for more attention by
health care providers to this subject and defining targets for
HDL cholesterol — How do I raise my patients good cholesterol?
Quratulain Shaikh, Ayeesha Kamran Kamal
Stroke Service and Vascular Fellowship Program, International Cerebrovascular Translational Clinical Research Training Program (Fogarty
International Center and National Institute of Neurologic Disorders and Stroke), Aga Khan University Hospital, Karachi, Pakistan.
Correspondence Author: Ayeesha Kamran Kamal. Email: ayeesha.kamal@aku.edu
Evidence Based Medicine
control and reference.
HDL cholesterol should be improved through diet rich
in omega 3 fatty acids like fish and exercise. Drugs like
Statins and Niacin can improve HDL levels by approximately
20% and are the mainstay of treatment. 
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